

# **Biological and Clinical Characteristics of Gene Carriers Far From Predicted Onset in the HD Young Adult Study: A Cross-Sectional Analysis**


Rachael I Scahill, Paul Zeun, Katherine Osborne-Crowley, Eileanoir B Johnson, Sarah Gregory, Christopher Parker, Jessica Lowe, Akshay Nair, Claire O'Callaghan, Christelle Langley, Marina Papoutsi, Peter McColgan, Carlos Estevez-Fraga, Kate Fayer, Henny Wellington, Filipe B Rodrigues, Lauren M Byrne, Amandan Heslegrave, Harpreet Hyare, Cristina Sampaio, Hanrik Zettererg, Hui Zhang, Edward J Wild, Geraint Rees, Trevor W Robbins, Barbara J Sahakian, Douglas Langbehn, Sarah J Tabrizi

## AIM: TO IDENTIFY THE EARLIEST HD CHANGES AND ROBUST OUTCOME MEASURES FOR CLINICAL TRIALS

### BACKGROUND

- Disease-modifying treatments are in development for HD - Intervention at the start of the neurodegenerative process whilst clinical function still intact may delay or prevent onset

### RESULTS



association with disease burden (q>0.48)

CONCLUSIONS Elevated NfL suggests early neuronal damage up to 24 years prior to symptom onset in the absence of functional impairment Reduced putamenal volumes may represent the start of neurodegeneration or may reflect different neurodevelopmental processes in gene carriers This study was supported by a Wellcome Trust Collaborative Award 200181/Z/15/Z and CHDI. Contact: r.scahill@ucl.ac.uk

likely in those closer to onset

#### METHODS

67 controls and 64 preHD approx. 24 years from expected onset underwent clinical, cognitive, neuropsychiatric, imaging and biofluid assessments



